Honz Pharmaceutical (300086.SZ): Net loss of 0.101 billion yuan in the first half of the year, turning into a loss compared to the same period last year.

Gelonghui Finance · Aug 26 04:56

Gelonghui August 26th | Honz Pharmaceutical (300086.SZ) announced its interim report for the first half of 2024, with revenue of 0.22 billion yuan, a year-on-year decrease of 33.88%; net income attributable to shareholders of the listed company was -0.101 billion yuan, a year-on-year loss from profit; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -0.105 billion yuan; basic earnings per share was -0.2241 yuan.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

康芝药业(300086.SZ)：上半年净亏损1.01亿元 同比转亏

Honz Pharmaceutical (300086.SZ): Net loss of 0.101 billion yuan in the first half of the year, turning into a loss compared to the same period last year.

Risk Disclaimer

Statement

康芝药业(300086.SZ)：上半年净亏损1.01亿元同比转亏